Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2016 Nov;82(5):1156-1157.
doi: 10.1111/bcp.13117.

Mechanistic target of rapamycin modulation: an emerging therapeutic approach in a wide variety of disease processes

Albert Ferro  1
Affiliations
Editorial

Mechanistic target of rapamycin modulation: an emerging therapeutic approach in a wide variety of disease processes

Albert Ferro. Br J Clin Pharmacol. 2016 Nov.
No abstract available

PubMed Disclaimer

References

    1. Sabatini DM, Erdjument‐Bromage H, Lui M, Tempst P, Snyder SH. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin‐dependent fashion and is homologous to yeast TORs. Cell 1994; 78: 35–43. - PubMed
    1. Brown EJ, Albers MW, Shin TB, Ichikawa K, Keith CT, Lane WS, et al. A mammalian protein targeted by G1‐arresting rapamycin‐receptor complex. Nature 1994; 369: 756–758. - PubMed
    1. Waldner M, Fantus D, Solari M, Thomson AW. New perspectives on mTOR inhibitors (Rapamycin, Rapalogs and TORKinibs) in transplantation. Br J Clin Pharmacol 2016; 82: 1158–1170. - PMC - PubMed
    1. Lutz M, Mielke S. New perspectives on the use of mTOR inhibitors in allogeneic haematopoietic stem cell transplantation and graft‐versus‐host disease. Br J Clin Pharmacol 2016; 82: 1171–1179. - PMC - PubMed
    1. Francipane MG, Lagasse E. Therapeutic potential of mTOR inhibitors for targeting cancer stem cells. Br J Clin Pharmacol 2016; 82: 1180–1188. - PMC - PubMed

Publication types

MeSH terms